Effexor and Pristiq Birth Defect Lawsuits

Baum, Hedlund, Aristei & Goldman’s lawyers are currently involved in potential birth defect litigation with the manufacturer of Effexor and Pristiq. The aim of this litigation will be to hold the manufacturer accountable by obtaining compensation for the infant victims and their parents. To qualify as a potential plaintiff in these cases, the mother of the child with the birth defect must have taken Effexor or Pristiq during her pregnancy.

Birth defects and congenital conditions associated with antidepressants:

• Cardiac (heart) defects
• PPHN (Persistent Pulmonary Hypertension of the Newborn)
• Neural-tube defects (brain and spinal cord)
• Craniosynostosis (skull defect)
• Infant omphalocele (abdominal wall defects)
• Clubfoot (one or both feet turn downward and inward)
• Anal atresia (complete or partial closure of the anus)
• Cleft lip and cleft palate
• Limb Defects

If your child was born with a birth defect and you took Effexor or Pristiq during your pregnancy, contact our Effexor birth defect lawyers or call 1-800-827-0087 now for a free consultation.

Baum Hedlund has successfully represented clients in every state in the U.S. In fact, we have represented more clients in antidepressant injury cases than any other law firm in the United States. 

While representing our clients, we dig deep into pharmaceutical company files to discover the truth about what  the company knew about the product’s risks, when the company knew of those risks and what efforts, if any, the company took to hide those risks.  Only through legal action can anyone gain access to this type of information, as acknowledged in an article written about our firm on June 20, 2008 in the Wall Street Journal. We obtain documents through our litigation that not even the FDA has seen. We fight hard to get this information into the public domain to prevent others from having to endure similar tragedies.

Let our team of experienced attorneys make sure you are effectively represented in your Effexor case.